Drug intelligence / Profile preview

NsG0202

Development stage: Phase 1
Lead developer: NsGene
Modality: Cell Therapies, Gene Therapies
Administration: Implant

Overview

**NsG0202** is an investigational, retrievable encapsulated cell biodelivery implant developed by NsGene for mild to moderate Alzheimer's disease. The stereotactically implanted device contains the genetically modified human retinal pigment epithelial cell line NGC-0295 within a semipermeable hollow-fiber membrane. The encapsulated cells continuously secrete nerve growth factor into the cholinergic basal forebrain, aiming to restore local trophic support for degenerating cholinergic neurons while preventing the implanted cells from contacting host tissue and allowing device retrieval. NsG0202 was evaluated in a small open-label Phase 1b study in Alzheimer's disease.

Other names: EC-NGF

Targets

NGFR (p75NTR)

Beyond the preview

Go deeper on NsG0202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NsG0202.

Explore the full profile